Press Release


Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference
Nov 30, 2022 09:21 JST
Eisai Co., Ltd. and Biogen Inc. announced today that the results from Eisai's large global Phase 3 confirmatory Clarity AD clinical study of lecanemab.
More info..

Eleven Experts from Leading Medical Institutions and Eight Experts from Eisai Publish Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease in the New England Journal of Medicine
Nov 30, 2022 08:31 JST
The rapid publication of the Clarity AD study results demonstrates Eisai's strong commitment to trust and transparency based on Eisai's human health care mission.
More info..

Eisai Announces Approval of Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies
Nov 29, 2022 18:28 JST
Eisai Co., Ltd. announced that its application for a partial change to label for Aricept (donepezil hydrochloride), a treatment for Alzheimer's disease and dementia with Lewy bodies (DLB) that was discovered and developed in-house, regarding dosage and administration for the treatment of DLB in Japan, has been approved today.
More info..

Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting
Nov 24, 2022 08:04 JST
Eisai Co., Ltd. announced today that the company will have a total of 34 poster presentations, including the latest data on its in-house discovered and developed anti-epileptic agent (AED) perampanel at the 76th American Epilepsy Society Annual Meeting (AES 2022), to be held in Nashville, Tennessee and virtually from December 2-6, 2022.
More info..

To Develop Japan's First Blood Biomarker-Based Diagnostic Workflow for Dementia Shimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research
Nov 22, 2022 13:10 JST
Shimadzu Corporation (Shimadzu), Eisai Co., Ltd. (Eisai), Oita University, and Usuki City Medical Association hereby announce the commencement of a cohort study using Usuki City as a demonstration site.
More info..

Eisai to Present Full Findings from Lecanemab Confirmatory Phase 3 Clinical Trial (Clarity AD) and Other Alzheimer's Disease Research at The 15th Clinical Trials on Alzheimer's Disease (CTAD) Conference
Nov 21, 2022 10:50 JST
Eisai's AD pipeline, including the company's investigational anti-microtubule binding region (MTBR) tau antibody (E2814), will be presented in four oral and ten poster presentations.
More info..

Metoject Subcutaneous Injection Syringe (Methotrexate) Launched In Japan For Rheumatoid Arthritis
Nov 16, 2022 10:46 JST
Eisai Co., Ltd. and nippon medac Co., Ltd. announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg syringe 0.15mL, 10mg syringe 0.20mL, 12.5mg syringe 0.25mL and 15mg syringe 0.30mL" (methotrexate, "MTX") in Japan.
More info..

Eisai to Divest Rights for Muscle Relaxant Myonal, Vertigo, and Equilibrium Disturbance Treatment Merislon in Asia to DKSH
Nov 07, 2022 08:15 JST
Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for muscle relaxant Myonal (generic name: eperisone hydrochloride) and vertigo and equilibrium disturbance treatment Merislon in Asia (9 countries/regions*) to a subsidiary of DKSH Holding Ltd
More info..

Eisai's Sales Subsidiary Collaborates with Thai Life Insurance to Support Access to Treatments for Dementia, Including Alzheimer's Disease, in Thailand
Nov 04, 2022 14:42 JST
Eisai Co., Ltd. announced today that its Thai sales subsidiary Eisai (Thailand) Marketing Co. Ltd. ("Eisai Thailand") made an agreement to collaborate in supporting access to treatments for dementia, including Alzheimer's disease, in Thailand with Thai Life Insurance Public Company Limited, a leading life insurance company in Thailand.
More info..

Eisai Satisfies All-case Study Requirement for Antiepileptic Agent Inovelon
Nov 02, 2022 17:34 JST
Eisai Co., Ltd. announced today that it has received notification from Japan's Ministry of Health, Labour, and Welfare (MHLW) that the "all-case study" specified post-marketing observational study condition.
More info..

Eisai Announces Plans to Submit Application for Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies Based on Results of Drug Reexamination
Nov 02, 2022 09:43 JST
Eisai Co., Ltd. announced today that it has received notification that Aricept (donepezil hydrochloride), a treatment for Alzheimer's disease and dementia with Lewy bodies that was discovered and developed in-house, has been granted Category 2* status based on the results of a reexamination of its efficacy, dosage and administration for the treatment of dementia with Lewy bodies (DLB) in Japan.
More info..

Eisai Completes Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan
Oct 04, 2022 15:44 JST
Eisai Co., Ltd. announced that, as part of the strategic investment towards the realization of its medium-term business plan "EWAY Future & Beyond", it has completed construction of the new injection/research building "Eisai Medicine Innovation Technology Solutions" ("EMITS") at the Kawashima Industrial Park located in Gifu Prefecture, Japan.
More info..

Eisai's Lecanemab Confirmatory Phase 3 Clarity AD Study Met Primary Endpoint
Sep 28, 2022 14:15 JST
Eisai Co., Ltd. and Biogen Inc. announced positive topline results from Eisai's large global Phase 3 confirmatory Clarity AD clinical trial of lecanemab.
More info..

Eisai: Metoject Subcutaneous Injection Syringe (Methotrexate) Approved in Japan for Rheumatoid Arthritis
Sep 26, 2022 19:14 JST
Eisai Co., Ltd. and nippon medac Co., Ltd. today that they have obtained manufacturing and marketing approval from the Japanese Ministry of Health, Labour and Welfare for the indication of the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg syringe 0.15mL, 10mg syringe 0.20mL, 12.5mg syringe 0.25mL and 15mg syringe 0.30mL" (methotrexate, "MTX") for the treatment of rheumatoid arthritis.
More info..

Eisai and Merck & Co., Inc. Present Results from Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
Sep 12, 2022 14:37 JST
Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada) today announced the first presentation of results from the final analysis of the Phase 3 LEAP-002 trial investigating LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA.
More info..

Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the European Society for Medical Oncology (ESMO) Congress 2022
Sep 12, 2022 08:00 JST
Eisai Co., Ltd. announced today results from a post hoc analysis of three randomized, pivotal, Phase 3 studies.
More info..

Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022
Sep 06, 2022 09:42 JST
Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2022, which is taking place virtually and in-person in Paris, France from September 9 to 13.
More info..

Eisai Inc. Collaborates with C2N to Build Awareness and Real-World Evidence for Blood-based Assays
Aug 24, 2022 15:18 JST
Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has entered into a memorandum of understanding with C2N Diagnostics ("C2N") that will seek to build awareness about how blood-based assays in the diagnosis for people living with cognitive impairment, including Alzheimer's disease (AD), may help patients receive a timely diagnosis and appropriate treatment.
More info..

Eisai and Lifenet Enter Into Capital and Business Alliance Agreement Aimed at Building Ecosystem to Reduce Burden of Medical and Nursing Care
Aug 09, 2022 17:09 JST
Eisai Co., Ltd. and LIFENET INSURANCE COMPANY announced today that they have entered into a capital and business alliance agreement to collaborate in dementia and other areas, with the aim of helping reduce the burden of medical and nursing care for people living in Japan's aging society.
More info..

Eisai Presents New Findings on Lecanemab's Investigational Subcutaneous Formulation and Modeling Simulation of ApoE4 Genotype on Aria-E Incidence at AAIC 2022
Aug 04, 2022 08:25 JST
Eisai Co., Ltd. and Biogen Inc. announced that Eisai presented new findings on a subcutaneous formulation of lecanemab (BAN2401) and the modeling simulation of the impact of ApoE4 genotype.
More info..

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial
Aug 04, 2022 08:05 JST
Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada) today announced that the Phase 3 LEAP-002 trial investigating LENVIMA.
More info..

Eisai Listed for 21st Consecutive Year in FTSE4Good Index Series
Jul 26, 2022 09:27 JST
Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 21st consecutive year since its initial inclusion in 2002.
More info..

Eisai to Present at The Alzheimer's Association International Conference (AAIC) 2022
Jul 26, 2022 08:04 JST
Eisai Co. Ltd announced today that the company will present research from its Alzheimer's disease (AD) pipeline, including new data for lecanemab (BAN2401).
More info..

U.S. FDA Accepts and Grants Priority Review for Eisai's Biologics License Application of Lecanemab
Jul 06, 2022 09:12 JST
Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) under the accelerated approval pathway for lecanemab.
More info..

E.Design Insurance and Eisai Enter Into Business Alliance
Jun 28, 2022 09:20 JST
E.design Insurance Co., Ltd., a direct non- life insurance company of the Tokio Marine Group, and Eisai Co., Ltd. announced today that both companies have entered into a business alliance agreement aiming to realize a society where people can safely enjoy driving for a longer period of their lives in anticipation of the advent of super-aging society, under the theme of "Improving Brain Health (brain performance) for Safe Driving."
More info..

Eisai Signs the Public-Private Partnership "Kigali Declaration" for Eliminating Neglected Tropical Diseases
Jun 24, 2022 10:55 JST
Eisai Co., Ltd. announced today that Eisai has signed the Kigali Declaration announced at the Kigali Summit on Malaria and Neglected Tropical Diseases (NTDs) on June 23, 2022 in Kigali, the capital of the Republic of Rwanda, and expressed Eisai's continued support for the elimination of NTDs towards the achievement of a road map for NTDs 2021-2030 launched by the World Health Organization (WHO).
More info..

Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal
Jun 22, 2022 13:05 JST
Eisai Co., Ltd. today announced publication of results from an early phase evaluation that aimed to estimate potential economic value of its investigational anti-amyloid-beta (Abeta) protofibril antibody lecanemab in people living with early Alzheimer's disease (AD) using a validated disease simulation model.
More info..

Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting
Jun 06, 2022 14:05 JST
Eisai Co., Ltd. announced today new investigational data from the platinum-resistant ovarian cancer (PROC) cohort expansion of a Phase 1 study (Study 101) evaluating the antibody drug conjugate (ADC) co-developed by Eisai and Bristol Myers Squibb, farletuzumab ecteribulin (MORAb-202).
More info..

Eisai to Present Latest Data on Lemborexant at The 36th Annual Sleep 2022 Meeting
Jun 03, 2022 15:37 JST
Eisai Co., Ltd. announced a total of seven poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 36th annual meeting of the Associated Professional Sleep Societies (SLEEP 2022), to be held from June 4 to 8, 2022, in Charlotte, NC, the United States.
More info..

Latest Release


More Latest Release >>